Re: Cai et al.: Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab (Ophthalmol Retina. 2024;8:733-743).

Ophthalmol Retina

Department of Ophthalmology, Chi Mei Medical Center, Tainan, Taiwan; School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Population Health Data Center, National Cheng Kung University, Tainan, Taiwan. Electronic address:

Published: January 2025

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.oret.2024.12.002	DOI Listing

Publication Analysis

Top Keywords

cai et al

et al risk

risk kidney

kidney failure

failure patients

patients blinding

blinding diseases

diseases receive

receive ranibizumab

ranibizumab aflibercept

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!